MAZZON AGURTO, ENRICO
Preferred name
MAZZON AGURTO, ENRICO
Main Affiliation
Email
emazzon@udd.cl
ORCID
0000-0001-7662-8556
Scopus Author ID
57214689246
19 results
Now showing 1 - 10 of 19
- Some of the metrics are blocked by yourconsent settings
Item type:Product, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Scopus© Citations 2 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Cervical Artery Dissections with and without stroke, risk factors and prognosis: a Chilean prospective cohort(2020); ;D. Rocha; ;C. De la BarraX. StecherScopus© Citations 7 3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Telestroke in Chile: 1 year experience at 7 hospitals(2019) ;Eloy Mansilla; ;Daniel Cárcamo ;Felipe JuradoLorena LaraScopus© Citations 6 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Low dosis of alteplase, for ischemic stroke after Enchanted and its determinants, a single center experience(2020); ; ;Gabriel Cavada ;Eloy MansillaAlexis Rojo<jats:p>Abstract Background: Low-dose alteplase (LrtPA) has been shown not to be inferior to the standard-dose (SrtPA) with respect to death/disability. Objective: We aim to evaluate the percentage of patients treated with LrtPA at our center after the ENCHANTED trial and the factors associated with the use of this dosage. Methods: Prospective study in consecutive patients with an acute stroke admitted between June 2016 and November 2018. Results: 160 patients were treated with intravenous thrombolysis, 50% female; mean age 65.4±18.5 years. Of these, 48 patients (30%) received LrtPA. In univariate analysis, LrtPA was associated with patient's age (p=0.000), previous modified Rankin scale scores (mRS) (p<0.000), hypertension (p=0.076), diabetes mellitus (p=0.021), hypercholesterolemia (p=0.19), smoking (p=0.06), atrial fibrillation (p=0.10), history of coronary artery disease (p=0.06), previous treatment with antiplatelet agents (p<0.000), admission International Normalized Ratio-INR (p=0.18), platelet count (p=0.045), leukoaraiosis on neuroimaging (p<0.003), contraindications for thrombolytic treatment (p=0.000) and endovascular treatment (p=0.027). Previous relevant bleedings were determinants for treatment with LrtPA. Final diagnosis on discharge of stroke mimic was significant (p=0.02) for treatment with SrtPA. In multivariate analysis, mRS (OR: 2.21; 95%CI 1.37‒14.19), previous antiplatelet therapy (OR: 11.41; 95%CI 3.98‒32.70), contraindications for thrombolysis (OR: 56.10; 95%CI 8.81‒357.80), leukoaraiosis (OR: 4.41; 95%CI 1.37‒14.10) and diagnosis of SM (OR: 0.22; 95%CI 0.10‒0.40) remained independently associated. Conclusions: Following the ENCHANTED trial, LrtPA was restricted to 30% of our patients. The criteria that clinicians apply are based mostly on clinical variables that may increase the risk of brain or systemic hemorrhage or exclude the patient from treatment with lytic drugs.</jats:p>Scopus© Citations 2 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 3Scopus© Citations 9 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Safety and efficacy of low-intensity versus standard monitoring following intravenous thrombolytic treatment in patients with acute ischaemic stroke (OPTIMISTmain): an international, pragmatic, stepped-wedge, cluster-randomised, controlled non-inferiority trial(Elsevier BV, 2025-05) ;Craig S Anderson ;Debbie Summers ;Menglu Ouyang ;Yi SuiBrenda Johnson2Scopus© Citations 15 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Efficacy of an avocado-based Mediterranean diet on serum lipids for secondary prevention after ischemic stroke: a randomized phase 2 controlled pilot trial(Springer Science and Business Media LLC, 2025-02-04); ; ;Valeska Vollrath ;Paula von GeldernCarolina VelásquezScopus© Citations 7 4